The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 10, 2019
Filed:
Aug. 18, 2016
Applicant:
Vapomed Limited, Nassau, BS;
Inventors:
Jacques Seguin, Launen, CH;
Emad Sabry, La Croix-Sur-Lutry, CH;
Assignee:
Vapomed Limited, Nassau, BS;
Primary Examiner:
Int. Cl.
CPC ...
A61M 11/00 (2006.01); A61K 45/06 (2006.01); A61K 31/135 (2006.01); A61K 31/4535 (2006.01); A61K 31/485 (2006.01); A61K 31/5517 (2006.01); A61M 15/08 (2006.01); A61K 9/00 (2006.01); A61M 31/00 (2006.01); A61M 39/22 (2006.01); A61M 16/00 (2006.01);
U.S. Cl.
CPC ...
A61M 11/00 (2013.01); A61K 9/0043 (2013.01); A61K 9/0078 (2013.01); A61K 31/135 (2013.01); A61K 31/4535 (2013.01); A61K 31/485 (2013.01); A61K 31/5517 (2013.01); A61K 45/06 (2013.01); A61M 15/08 (2013.01); A61M 31/00 (2013.01); A61M 39/22 (2013.01); A61M 2016/0021 (2013.01); A61M 2205/33 (2013.01); A61M 2205/3334 (2013.01); A61M 2205/3569 (2013.01); A61M 2205/50 (2013.01); A61M 2205/52 (2013.01); A61M 2205/583 (2013.01); A61M 2205/587 (2013.01); A61M 2205/8206 (2013.01); A61M 2205/8256 (2013.01); A61M 2205/8262 (2013.01); A61M 2210/0618 (2013.01); A61M 2230/005 (2013.01); A61M 2230/20 (2013.01); A61M 2230/205 (2013.01); A61M 2230/42 (2013.01); A61M 2230/435 (2013.01);
Abstract
Devices and methods for sequential aerosolized administration of pharmaceutical agents. A portable device may be used to administer an initial dose of an active formulation comprising at least one first pharmaceutical agent and a subsequent dose of an active formulation comprising at least one second pharmaceutical agent that may have the effect of countering, enhancing, or mitigating the first pharmaceutical agent.